TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets clinical trials

First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies (The FIOL-study)

This study looks at a medicine called osimertinib (also known as Tagrisso) for a type of lung cancer with a specific gene change (EGFR mutation). We want to see how well it shrinks tumours and helps people live longer, while also checking if it's safe.